Bifido
비피도 · 238200
Consumer Staples Food & Beverage · KOSDAQ
Market cap US$16M (₩22B)
Overview
Bifido makes probiotic supplements, live beneficial bacteria in powder and finished-product form, designed to support gut health for consumers.
It supplies these products under its own brand, BIFIDO LAB, and also provides ODM (original design manufacturing) services, developing and producing probiotic goods for other companies under their own labels. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core business rests on proprietary bacterial strains originally isolated from Korean infants, and it is also developing microbiome-based therapeutic drugs as a separate pipeline alongside its consumer health business.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$13.5M
- FY2024US$8.9M
- FY2025US$14.3M
Operating profit
- FY2023−US$249K
- FY2024−US$3.3M
- FY2025US$1M
Net income
- FY2023US$784.2K
- FY2024−US$3.9M
- FY2025−US$139.7K
Key ratios (FY2025)
Why it matters
Bifido holds US FDA new dietary ingredient and safety certifications for its proprietary strains, and one strain has been registered in the United States Pharmacopeia.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?